Differential Gene Expression of Pancreatic Cancer Cell Line Capan-2 in Response to Gemcitabine plus BVDU (RP101) Combinatorial Treatment

Publication Type:

Journal Article


Biomed Data J., Volume 1, Issue 2, p.07-09 (2015)


cancer chemotherapy Prevention of chemoresistance HSP27 HSPB1 BVDU (RP101) pancreatic adenocarcinoma


A main obstacle in cancer chemotherapy is the rapid development of resistance by cancer cells. The heat shock protein HSP27 has been found as one of the key players driving resistance development. HSP27 is overexpressed in many kinds of cancer. It influences cellular pro­cesses like apoptosis, DNA repair, recombination, and metastasis. As a result, cancer cells evade apoptosis and develop resistance towards cy­tostatic drugs such as Gemcitabine (used as standard therapy in pan­creatic cancer). To address this problem the HSP27-inhibitor BVDU ((E)-5-(2-Bro­movinyl)-2′-deoxyuridine, RP101) was administered in combination with Gemcitabine to prevent resistance development. In the study design, the human pancreatic adenocarcinoma cell line Capan-2 was exposed to Gemcitabine alone and in combination with BVDU. Differential gene expression was displayed using DNA microarrays.This paper presents the resulting dataset, with pairwise comparison of control (untreated), Gemcitabine-, BVDU-, and Gemcitabine+BVDU - treated probes. The five spreadsheet files are openly accessible for vali­dation, re-use and aggregation in future research.

Full text: 

19,712 times
# File Name Number of Downloads
1 01201_1_BVDU_vs_control.ods 1652
2 01201_2_Gemcitabine_vs_control.ods 1827
3 bmdj.01201_Expression Profiling.pdf 3219
4 01201_5_Gemcitabine+BVDU_vs_BVDU.ods 1086
5 01201_1_BVDU_vs_control.xls 2006
6 01201_5_Gemcitabine+BVDU_vs_BVDU.xls 1390
7 01201_4_Gemcitabine+BVDU_vs_Gemcitabine.xls 1555
8 01201_3_Gemcitabine+BVDU_vs_control.xls 1293
9 01201_2_Gemcitabine_vs_control.xls 1841
10 01201_4_Gemcitabine+BVDU_vs_Gemcitabine.ods 1137
11 01201_3_Gemcitabine+BVDU_vs_control.ods 1102